We report a pediatric case of CAEBV and T cell-based Hodgkin's-like disease successfully treated with allo PBSCT from an HLA-matched sibling. The diagnosis of CAEBV was made from clinical signs and the presence of the EBV genome in PBMC and tumor cells. Conditioning with busulfan (BU) + etoposide (VP16) + cyclophosphamide (CY) was effective and well tolerated. EBV was totally eradicated by 3 months after allo PBSCT. Although she suffered from chronic GVHD of the liver, she has been well and free of disease for 47 months since PBSCT. We suggest allo PBSCT for CAEBV as a potent therapeutic strategy for eradication of the EBV genome and allowing immunological reconstitution.
Bone Marrow Transplantation (2002) 29, 531–533. doi:10.1038/sj.bmt.1703392
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Rickinson AB . Chronic, symptomatic Epstein–Barr virus infections Immunol Today 1986 7: 13 15
Ishida Y, Yokota Y, Tauchi H et al. Ganciclovir for chronic active Epstein–Barr virus infection Lancet 1993 341: 560 561
Sakai Y, Ohga S, Tonegawa Y et al. Interferon α therapy for chronic active Epstein–Barr virus infection: potential effect on the development of T-lymphoproliferative disease J Pediatr Hematol Oncol 1998 20: 342 346
Kawa-Ha K, Franco E, Doi S et al. Successful treatment of chronic active Epstein–Barr virus infection with recombinant interleukin-2 Lancet 1987 i: 154
Kuzushima K, Yamamoto M, Kimura H et al. Establishment of Epstein–Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection Clin Exp Immunol 1996 103: 192 198
Kimura H, Morita M, Yabuta Y et al. Quantitative analysis of Epstein–Barr virus load by using a real-time PCR assay J Clin Microbiol 1999 37: 132 136
Su IJ, Hsieh HC . Clinicopathological spectrum of Epstein–Barr virus-associated T cell malignancies Leuk Lymphoma 1992 7: 47 53
Teshima T, Miyaji R, Fukuda M et al. Bone marrow transplantation for Epstein–Barr virus-associated natural killer cell-large granular lymphocyte leukemia Lancet 1996 347: 1124
Imashuku S, Naya M, Yamori M et al. Bone marrow transplantation for Epstein–Barr virus-related clonal T cell proliferation associated with hemophagocytosis Bone Marrow Transplant 1997 19: 1059 1060
Takami A, Nakao S, Yachie A et al. Successful treatment of Epstein–Barr virus-associated natural killer cell large granular lymphocytic leukemia using allogeneic peripheral blood stem cell transplantation Bone Marrow Transplant 1998 21: 1279 1282
Fujii N, Takenaka K, Hiraki A et al. Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein–Barr virus infection Bone Marrow Transplant 2000 26: 805 808
We are grateful to Koh Kaneko MD (Department of Pathology, Japan Red Cross Ohmiya Hospital) for his help.
About this article
Cite this article
Taketani, T., Kikuchi, A., Inatomi, J. et al. Chronic active Epstein–Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 29, 531–533 (2002). https://doi.org/10.1038/sj.bmt.1703392
- malignant lymphoma
- allo PBSCT
- EBV in situ hybridization